Promacta (eltrombopag) is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program, using the contact information at the bottom of this page.
FDA Drug Safety Communication: Modified Risk Evaluation and Mitigation Strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag)[ARCHIVED]
FDA announces changes to risk strategy requirements for 2 drugs to treat low platelet counts[ARCHIVED]
FDA news release (12/6/2011)
- FDA Oncologic Drugs Advisory Committee Meeting, 5/30/2008